"Interleukin-6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.
| Descriptor ID |
D015850
|
| MeSH Number(s) |
D12.644.276.374.465.224 D12.776.467.374.465.202 D23.529.374.465.224
|
| Concept/Terms |
Interleukin-6- Interleukin-6
- Interleukin 6
- IL6
- B-Cell Stimulatory Factor 2
- B-Cell Stimulatory Factor-2
- Differentiation Factor-2, B-Cell
- Differentiation Factor 2, B Cell
- B-Cell Differentiation Factor-2
- B Cell Differentiation Factor 2
- BSF-2
- Hybridoma Growth Factor
- Growth Factor, Hybridoma
- IFN-beta 2
- Plasmacytoma Growth Factor
- Growth Factor, Plasmacytoma
- Hepatocyte-Stimulating Factor
- Hepatocyte Stimulating Factor
- MGI-2
- Myeloid Differentiation-Inducing Protein
- Differentiation-Inducing Protein, Myeloid
- Myeloid Differentiation Inducing Protein
- B-Cell Differentiation Factor
- B Cell Differentiation Factor
- Differentiation Factor, B-Cell
- Differentiation Factor, B Cell
- IL-6
- Interferon beta-2
- Interferon beta 2
- beta-2, Interferon
- B Cell Stimulatory Factor-2
- B Cell Stimulatory Factor 2
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-6".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-6".
This graph shows the total number of publications written about "Interleukin-6" by people in this website by year, and whether "Interleukin-6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 1 | 6 |
| 1995 | 7 | 4 | 11 |
| 1996 | 6 | 2 | 8 |
| 1997 | 5 | 4 | 9 |
| 1998 | 14 | 8 | 22 |
| 1999 | 5 | 7 | 12 |
| 2000 | 10 | 11 | 21 |
| 2001 | 10 | 4 | 14 |
| 2002 | 6 | 13 | 19 |
| 2003 | 5 | 14 | 19 |
| 2004 | 6 | 19 | 25 |
| 2005 | 8 | 16 | 24 |
| 2006 | 9 | 27 | 36 |
| 2007 | 10 | 20 | 30 |
| 2008 | 12 | 15 | 27 |
| 2009 | 11 | 23 | 34 |
| 2010 | 6 | 15 | 21 |
| 2011 | 11 | 17 | 28 |
| 2012 | 13 | 19 | 32 |
| 2013 | 8 | 18 | 26 |
| 2014 | 2 | 25 | 27 |
| 2015 | 11 | 13 | 24 |
| 2016 | 6 | 12 | 18 |
| 2017 | 6 | 18 | 24 |
| 2018 | 6 | 5 | 11 |
| 2019 | 5 | 8 | 13 |
| 2020 | 3 | 9 | 12 |
| 2021 | 5 | 12 | 17 |
| 2022 | 1 | 13 | 14 |
| 2023 | 3 | 12 | 15 |
| 2024 | 3 | 10 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-6" by people in Profiles.
-
NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children. J Immunol. 2024 Nov 15; 213(10):1452-1466.
-
Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis. Ann Med. 2024 Dec; 56(1):2396559.
-
Quality of life and survivorship in patients with low-grade ovarian cancer. Gynecol Oncol. 2024 Nov; 190:96-103.
-
Whole genome sequencing based analysis of inflammation biomarkers in the Trans-Omics for Precision Medicine (TOPMed) consortium. Hum Mol Genet. 2024 08 06; 33(16):1429-1441.
-
LPS-induced whole-blood cytokine production and depressive symptoms in dementia spousal caregivers: The moderating effect of childhood trauma. Psychoneuroendocrinology. 2024 Oct; 168:107140.
-
Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 responses. J Allergy Clin Immunol. 2024 Nov; 154(5):1169-1179.
-
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis. 2024 Jun 14; 78(6):1490-1503.
-
Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024 Jun 01; 9(6):497-506.
-
Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression. Front Endocrinol (Lausanne). 2024; 15:1408312.
-
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024 Feb 14; 15(1):1373.